home / stock / aplt / aplt news


APLT News and Press, Applied Therapeutics Inc. From 05/12/22

Stock Information

Company Name: Applied Therapeutics Inc.
Stock Symbol: APLT
Market: NYSE
Website: appliedtherapeutics.com

Menu

APLT APLT Quote APLT Short APLT News APLT Articles APLT Message Board
Get APLT Alerts

News, Short Squeeze, Breakout and More Instantly...

APLT - Applied Therapeutics GAAP EPS of -$0.88

Applied Therapeutics press release (NASDAQ:APLT): Q1 GAAP EPS of -$0.88. Cash and cash equivalents and short-term investments totaled $55.7 million as of March 31, 2022, compared with $80.8 million at December 31, 2021. For further details see: Applied Therapeutics GAAP EPS of -$0.88

APLT - Applied Therapeutics Reports First Quarter 2022 Financial Results

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...

APLT - Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Sorbitol correlates with disease severity in patients with SORD Deficiency AT-007 treatment substantially reduced sorbitol levels in a pilot study in SORD Deficiency Sorbitol elevation results in mitochondrial dysfunction, neuronal loss, and climbing defects in a drosoph...

APLT - Watch for Continued Gains in Shares of Applied Therapeutics Inc. (APLT)

Applied Therapeutics Inc. (NASDAQ:APLT) traded at a new 52-week high today of $57.37. This new high was reached on above average trading volume as 6.2 million shares traded hands, while the average 30-day volume is approximately 295,000 shares. Applied Therapeutics Inc is a clinical-stag...

APLT - Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster presentatio...

APLT - ORIC, Unity Biotechnology top healthcare gainers; SELLAS, Pulse Biosciences lead losers' pack

Gainers: ORIC Pharmaceuticals (ORIC) +14%. Unity Biotechnology (UBX) +13%. Applied Therapeutics (APLT) +11%. Genetron (GTH) +11%. Clarus Therapeutics (CRXT) +8%. Losers: SELLAS Life Sciences SLS -39%. Pulse Biosciences (PLSE) -22%. Spero Therapeutics SPRO&#x...

APLT - TCR2 Therapeutics leads healthcare gainers; ORIC Pharmaceuticals, Graphite Bio among losers

Gainers: TCR2 Therapeutics (TCRR) +16%. Precision BioSciences (DTIL) +16%. Alzamend Neuro (ALZN) +15%. BioSig Technologies (BSGM) +13%. Applied Therapeutics (APLT) +13%. Losers: ORIC Pharmaceuticals (ORIC) -29%. Applied Genetic Technologies (AGTC) -28%. NeuroSense Therapeutics (NRSN...

APLT - Applied Therapeutics (APLT) Investor Presentation - Slideshow

The following slide deck was published by Applied Therapeutics, Inc. in conjunction with this event. For further details see: Applied Therapeutics (APLT) Investor Presentation - Slideshow

APLT - Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics

NEW YORK, March 16, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced their abstract #OP...

APLT - Applied Therapeutics GAAP EPS of -$4.12 beats by $0.31

Applied Therapeutics press release (NASDAQ:APLT): FY GAAP EPS of -$4.12 beats by $0.31. Cash and cash equivalents and short-term investments totaled $80.8 million as of December 31, 2021, compared with $96.8 million at December 31, 2020. For further details see: Applied Therapeutics GAA...

Previous 10 Next 10